| 11-1474A | Accountability for Cancer Care through Undoing Racism and Equity (ACCURE) | Open |
| 13-2058 | Internet Tobacco Vendors Youth Purchase Survey | Open |
| 15-3137 | A Feasibility Study of Antineoplastic Drug Exposure among Nursing Assistants | Open |
| 17-1493 | Expanded Access of Neratinib for Use with Capecitabine in Patients with Metastatic Breast Cancer and CNS Metastasis | Open (affiliates only) |
| 20120139 | A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
| Open |
| 201404139 | Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients with Incurable SCCHN | Open |
| 9785-CL-0123 | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | Open |
| A031102-CIRB | A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (Tip) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (Ti-Ce) As First Salvage Treatment in Relapsed or Refractory Germ Cell
Tumors
| Open |
| A091101 | Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) –a Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck | Open |
| AMGEN359 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of
Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of
Recurrence (D-CARE) | Open (affiliates only) |
| AMGEN482 | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With
Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly
Diagnosed Multiple Myeloma | Open (affiliates only) |
| ASG-22CE-13-2 | A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of
ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial
Cancer and Other Malignant Solid Tumors that Express Nectin-4 | Open |
| B2151009 | Phase 1B Study to Assess the Safety, Tolerbaility, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC) | Open |
| CA209-274 | A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma | Open |
| CALGB90601-CIRB | A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma | Open (affiliates only) |
| CCCWFU-60A02 | HIGH POINT- CCCWFU #60A02 - A Phase II Randomized Placebo Controlled, Double Blinded Trial to Evaluate the Effects of Fruit and Vegetable Extracts on Intermediate Biomarkers in Head and Neck Cancer Patients | Open (affiliates only) |
| COG-AALL0331 | Standard Risk B-precursor Acute Lymphoblastic Leukemia | Open |
| EA8141 | A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma | Open |
| EMR200647-001 | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indication | Open |
| ETCTN9947-CIRB | A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma | Open |
| GO30140 | An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors. | Open |
| GU14-182 | A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer | Open |
| INCB-54828-201 | A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations | Open |
| LCCC1241 | Complementary and Alternative medicine use at UNC clinics | Open |
| LCCC1527 | Evaluation of the Chemotherapy Toxicity Risk Score for Treatment Decision in Elderly Patients with Advanced Solid Cancer | Open |
| LCCC1529 | New Approaches to Identifying Malignancy in Cystic Kidney Lesions in Patients with Chronic Kidney Disease | Open |
| LCCC1531 | Pembrolizumab in Systemic Treatment-Naïve Distant Metastatic Melanoma and Exploration of use of 11Cmethyl-L-tryptophan (AMT) PET at Baseline as a Predictive Imaging Biomarker of Response | Open |
| MM-398-01-01-02 | A Phase 1 Study in Patients Treated with MM-398 (Nanoliposomal Irinotecan, nal-IRI,) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment | Open |
| MSKCC-13-074 | Randomized phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) vs. bleomycin, etoposide and cisplatin (BEP) for patients with previously untreated intermediate- and poor- risk germ cell tumors | Open |
| NRG-BR003-CIRB | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High- Risk Node-Negative Triple-Negative Invasive Breast Cancer | Open |
| NRG-GY004 | A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Open |
| PCRC-14-07 | Caregiver-‐guided pain management training in palliative care | Open |
| RTOG1008 | A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
| Open |
| SGN19A-003 | A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide,
carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse
large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant | Open |
| SNDX-275-0601 | A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small cell Lung Cancer and Melanoma | Open |
| TEST4 | A four part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine,or Concurrent BKM120 and Capecitabine and Trastuzumab, in Patients with Metastatic Colon Cancer (Test4) | Open |
| WO30070 | A Phase Iii, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti−Pd-L1 Antibody) In Combination With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone In Patients With Untreated Locally Advanced Or Metastatic Urothelial Carcinoma Who Are Ineligible For Cisplatin-Based Therapy | Open |
| X4P-001-RCCB | A Phase 1b/2a Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell Carcinoma | Open |